Magnitude of delayed turnaround time of laboratory results in Amhara Public Health Institute, Bahir Dar, Ethiopia

Melashu Balew Shiferaw * and Gizachew Yismaw

Abstract

Background: Clinical decisions depend on timely laboratory result reporting. The timeliness is commonly expressed in turnaround time and serves as a quality improvement tool to assess the effectiveness and efficiency of the laboratory. According to the International Organization for Standardization (ISO) guidelines, each laboratory shall establish turnaround times for each of its examinations that reflect clinical needs, and shall periodically evaluate whether or not it is meeting the established turnaround times. Therefore, this study aimed to assess the TAT of laboratory results done in the reference laboratories of the Amhara Public Health Institute, Bahir Dar, Ethiopia.

Methods: A retrospective cross sectional study was carried out from 01 January to 31 September 2018. Each patient sample was considered as a study unit. Nine months data were extracted from the sample tracking log and from the Laboratory Information System (LIS) database. Descriptive and summary statistics were calculated using SPSS version 20.0 statistical software.

Results: A total of 34,233 patients samples were tested during the study period. Monthly average TAT ranged from 38.6 to 51.3 days for tuberculosis (TB) culture, 5.3 to 42.4 days for exposed infant diagnosis (EID) for HIV, 8.4 to 26 days for HIV 1 viral load, and 1.9 to 3.5 days for TB genexpert tests. Compared with the standard, 76.5% of the viral load, 68.1% of the EID for HIV and 53.8% of the TB genexpert tests had delayed TAT. Repeated reagent stock out, high workload, activities overlapping, and staff turnover were major reasons for the result delays.

Conclusions: There was a delayed turnaround time of laboratory results in APHI. HIV viral load, EID and TB genexpert results were the most affected tests. Workload reduction plan, proper stock management, specific work assignment and trained staff retention are important approaches to minimize the delayed TAT in the setting.

Keywords: Delayed TAT, APHI, Laboratory, Ethiopia

Background

Turnaround time (TAT) is defined as the elapsed time between two specified points through pre-examination, examination and post-examination processes of the laboratory testing [1]. It consists of the intervals from order placement to specimen collection, transportation to the laboratory, accessioning in the laboratory, centrifugation, aliquoting, additional pre-analytic steps if necessary, transport times within and between laboratories, analysis time, the time after completion of analysis until result verification, and the time it takes for the clinical team to be informed of the result [2].

In order to ensure quality diagnostic service, the laboratory should provide accurate, reliable and timely results to the customers. The timeliness is commonly expressed in TAT, which is often used by the clinicians as the benchmark for laboratory performance, and serves as a quality indicator to assess the effectiveness and efficiency of the total testing process in addition to clinicians’ and patients’ satisfaction [3–6].

Assessment and improving turnaround time is essential for laboratory quality management [2]. According to the International Organization for Standardization (ISO) guidelines, the laboratory, in consultation with the users, shall establish turnaround times for each of its examinations that reflect clinical needs. The laboratory shall

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
periodically evaluate whether or not it is meeting the established turnaround times [1]. The laboratory plays a crucial role to provide objective information. In real practice, 60 to 70% of the objective information on the patient’s chart is laboratory information [7].

Delays in laboratory results reporting would cause a delay in the diagnosis and management of patients. A study showed that there was 43% treatment delay and 61% increased length of stay in the emergency department [8]. Moreover, a slow TAT can lead to increase in requests which results in duplication of the test [9]. This further increases the workload in the laboratory, and may again increase the cost burden of the health care [10]. Therefore, faster TAT is universally desirable for efficient and effective management of patients in addition to save time and money [8].

When there is a delay, understanding the root causes of high TAT using evidence-based methods are essential for quality improvements. Consequently, regulatory and accrediting bodies advise clinical laboratories to target TAT in their continual improvement process [8, 11]. However, information about the problem is limited in the region including our setting. Therefore, this study was designed to assess the magnitude of delayed TAT of laboratory tests in Amhara Public Health Institute, Bahir Dar, Ethiopia.

**Methods**
A retrospective cross sectional study was carried out to assess the trends of TAT of laboratory tests performed in the reference laboratories of APHI. The institute is located in Bahir Dar town Ethiopia to serve as a reference laboratory for peripheral laboratories in Amhara region in addition to providing active patient laboratory diagnostic service provision. The institute has seven reference laboratories namely HIV molecular, measles/rubella, immunology and hematology, clinical chemistry, parasitology, basic microbiology and TB reference laboratories.

The patients who had final released results at APHI central reception were included in this study. Therefore, each sample was considered as a sampling unit to study the TAT of the test. As a requirement, the reference laboratories established specific TAT of each test to follow as a quality indicator. The laboratories again established a target for each test. For instance, EID and HIV viral load tests had a target TAT of 10 days each. TB genexpert and clinical chemistry tests had also targeted TAT of two hours each. As a quality indicator of good performance, at least 90% of the tests should be released within the established TAT from the central reception. In APHI all patient samples were submitted at the central reception, evaluated based on established criteria, entered to the Polytech Laboratory Information System (Comp Pro Med, Inc., USA) and samples dispatched to each respective laboratories, and then results sent back to central reception after investigation and result verification (Fig. 1). In addition, referral samples collected at different health facilities were transported to the APHI

---

Fig. 1 Process of work flow for laboratory diagnosis in the reference laboratories of the APHI, 2018. Abbreviations: LIS, laboratory information system; Lab, laboratory.
through postal and/or vehicle dedicated to the specimen transport. All specimens transported and submitted to the APHI reception, and after laboratory analysis results were back to the health facilities through postal services. All submitted samples at APHI reception with complete information (from 01 January to 31 September 2018) were included consecutively. In this study, data extraction tool was prepared by the principal investigator. The tool was pretested and modifications were made after the pretest to ensure the quality of the data extraction tool. In the central reception, information about received samples was available from the specimen tracking log. The tracking log was reviewed and necessary data related to TAT were collected from the tracking log and from the Polytech Laboratory Information System (Comp Pro Med, Inc., USA) database. Then, TAT for each submitted specimen having final results was calculated by subtracting the time of specimen submission from the time of result released at the APHI central reception. This TAT did not include travel to the testing laboratory. The TAT of each patient result was graded as good if it was released within the time frame established by the APHI laboratories. Moreover, the general performance of the laboratory was rated as good if at least 90% of the patient results were released within the established TAT on a monthly basis.

We also interviewed laboratory personnel who worked in the reference laboratories and in the central receptions of the APHI to describe the causes of delayed TAT. Reagent stock status, activities overlapping, equipment status and workload statistics with number of laboratory personnel were the main focus of the interviews in addition to document review.

The data were analyzed using SPSS 20.0 (IBM Corp., Armonk, NY); cleaning analysis of missing values were checked; variables such as type of laboratory tests done in APHI, date and time of specimen processing, days of reagent stock out, overlapping of other activities and workload were analysed. TAT indicators such as proportions and mean were calculated [12, 13].

## Results

A total of 34,233 samples were diagnosed in the APHI reference laboratories during the nine month period, January to September 2018. HIV viral load and leishmaniasis diagnosis showed the highest and the lowest number of tests done with 26,984 and 21 total testing, respectively. Moreover, a total of 2484 immune hematology, 1393 EID and 1236 TB genexpert tests were performed. The workload was improved time to time. However, clinical chemistry laboratory had a high workload in May 2018 due to sudden increase in test volumes. Measles, basic microbiological culture and sensitivity, TB culture and chemistry accounted 320, 421, 946 and 428 test volumes, respectively. The highest test statistics across the months were 5497, which was recorded in March and the lowest test statistics, 2636, was recorded in September 2018 (Table 1).

The average TAT of each test varied across each test parameter. Over the nine month period, the average TAT for HIV viral load was 26 days in February and 8.4 days in May 2018. EID showed greater differences with a maximum of 42.4 and a minimum of 5.3 days to provide patient results. The fastest TAT was documented for immunohematoloy and clinical chemistry tests that were done in two hours. The average time taken for genexpert was between 1.9 and 3.5 days. TB culture took more time due to the nature of the TB bacteria that wasted from 38.6 to 51.3 days to get final patient results. Looking at these trends, most of the tests had improved average monthly TAT in April, May, June and July 2018 (Table 2).

Among the total tests requested in the APHI reference laboratories, HIV viral load, EID and TB genexpert test results were out of the established 90% target over the

### Table 1 Number of laboratory tests performed at APHI from January to September, 2018

| SN | Test type                  | Number of tests | Total |
|----|----------------------------|-----------------|-------|
| 1  | HIV Viral load             | 3725            | 26,984|
| 2  | EID                        | 403             | 1393  |
| 3  | MDR TB culture             | 112             | 946   |
| 4  | Genexpert                  | 190             | 1236  |
| 5  | Basic culture and sensitivity | 15   | 421   |
| 6  | Clinical chemistry         | 10              | 428   |
| 7  | Leishmania                 | 2               | 21    |
| 8  | Measles                    | 33              | 320   |
| 9  | Immunohematology           | 393             | 2484  |
|    | **Total**                  | **4883**        | **34,233** |

Abbreviations: EID exposed infant diagnosis, HIV human immunodeficiency virus, TB tuberculosis
nine months. About 76.5% (20,634/26,984) of viral load, 53.8% (665/1236) of TB genexpert and 68.1% (984/1393) of EID results had delayed TAT in the study period. EID TAT was out of the target for eight months follow up. Interestingly, in May 2018, all of the EID samples were analyzed within the established TAT target. Similarly, TB culture was also achieved above the target except in August 2018 when only 87.8% of the TB culture results were released within the established TAT. The TAT of basic culture and sensitivity tests were out of the established TAT in January, April, August and September. In between the TATs improved. However, it has become delayed since August 2018(Fig. 2) as a result of staff turnover. Other tests (Leishmania culture, measles, clinical chemistry and immunohematology) results were released within the established laboratory targeted TAT.

During the study period, there were repeated stock outs of both viral load and EID reagents specifically happened. In February and April 2018, both of the tests lasted for 14 days of stock out. Equipment downtime, and low equipment capacity to perform high number of samples were also challenges in the institute. Moreover, the number of personnel assigned to testing was lower compared to the workload statistics in addition to overlapping of other activities in the testing laboratory.

**Discussion**

Appropriate and timely clinical decisions depend on timely reporting, which in turn affects patient outcome. Hence, a rapid laboratory turnaround time is important to manage patients in a timely manner. So, analysis of this time interval helps to determine the cause of delay, which is then followed by the improvement in

| SN | Test type                      | Target TAT | TAT Jan | TAT Feb | TAT Mar | TAT Apr | TAT May | TAT Jun | TAT Jul | TAT Aug | TAT Sep |
|----|--------------------------------|------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 1  | Viral load                     | 10 days    | 26.1    | 19      | 21      | 11.4    | 8.4     | 9.9     | 15      | 13.8    | 12      |
| 2  | EID                            | 10 days    | 42.4    | 20.3    | 11      | 12.5    | 13      | 5.3     | 19      | 27      | 11      |
| 3  | MDR TB                         | 64 days    | 51.3    | 44.7    | 51.1    | 44      | 38.6    | 46      | 45      | 45.6    | 48      |
| 4  | Genexpert                      | 2 days     | 2.69    | 3       | 2.4     | 3.5     | 2.4     | 2.2     | 3.3     | 1.9     | 2.4     |
| 5  | Basic culture and sensitivity  | Blood      | 8 days  | 8       | 7       | 7       | 7       | 7       | 7       | 7       | 7       |
|    |                                | Others     | 3 days  | 2.3     | 2.8     | 2.5     | 3       | 3.3     | 3       | 3.5     | 3.5     |
| 6  | Clinical chemistry             | 2 h        | 2       | 2       | 20.3    | 10      | 9.15    | 2.2     | 1.5     | 1.5     | 2.4     |
| 7  | Measles                        | 7 days     | 21      | 9.9     | 9       | 7.7     | 10.7    | 7       | 7       | 7       | 7       |
| 8  | Immunohematology               | 1 h        | 2.5     | 2.3     | 1.84    | 3.4     | 14.1    | 18.0    | 21      | 14.3    | 17.6    |

**Table 2** Trends of average TAT of laboratory tests in APHI from January to September 2018

Abbreviations: EID exposed infant diagnosis, HIV human immunodeficiency virus, MDR multidrug resistance, TB tuberculosis

Other cultures: Pus, urine, stool, genital swab, ear swab and throat

**Fig. 2** Trends of laboratory results released based on the established TAT target of APHI from January to September 2018. Abbreviations: EID exposed infant diagnosis; TB, tuberculosis; MDR, multidrug resistance; VL, viral load
load testing. Documents revealed that very early infant to be released within the target TAT like that of the viral established 10 days target and at least 90% of the results target of the APHI laboratory. The APHI laboratory TAT, still it needs more improvement to accomplish the EID services [22]. However, compared to the established in Kenya that reported an average TAT of 24.7 days for finding was relatively better compared to a study done from June 2018, it was again increased since July. This trend of TAT became continuously improved from January with a range of 5.3 to 42.4 days. Although the average over the nine month period. It took 17.9 days on average enough manpower in addition to planning of overlapped by ensuring a consistent supply and placement of technical staff, and having increased number of test menus [15, 16]. A study conducted in Malawi also showed longer TAT of viral load testing was mainly linked with specimen origin, type and testing laboratory [17]. Delayed TATs could greatly impact early management and care of the patients. Specifically, it could delay initiation of treatment adherence counseling and/or switch to second line antiretroviral therapy (ART) in patients experiencing treatment failure, which further contributes to poorer health outcomes, prolonged immune activation, development of drug resistance, and increased mortality [18–21]. The problem could be solved by ensuring a consistent supply and placement of enough manpower in addition to planning of overlapped activities in the institute laboratories. This would be helpful in providing better service to the physicians and patients.

Moreover, 68.1% of the EID results had delayed TAT over the nine month period. It took 17.9 days on average with a range of 5.3 to 42.4 days. Although the average trend of TAT became continuously improved from January to June 2018, it was again increased since July. This finding was relatively better compared to a study done in Kenya that reported an average TAT of 24.7 days for EID services [22]. However, compared to the established TAT, still it needs more improvement to accomplish the target of the APHI laboratory. The APHI laboratory established 10 days target and at least 90% of the results to be released within the target TAT like that of the viral load testing. Documents revealed that very early infant diagnosis, defined as testing within two weeks of life, combined with rapid ART initiation could prevent the observed decline in immunologic function and clinical deterioration and further reduce infant mortality [23].

Currently, priority is given more to tuberculosis prevention and control. One of the strategies is early diagnosis and treatment. In the institute, TB culture and genexpert tests have been given with the aim to deliver results in 15 to 48 for positive and 42–64 days for negative cultures, and 2 days for genexpert testing. Although the average TAT of TB culture seemed long time (38.6 to 51.3 days), it was due to the nature of the testing that TB bacteria need more time to grow. In a pilot study, the TAT of the Xpert MTB/RIF assay in an outpatient setting was shorter than those of AFB smears, liquid culture, solid culture and drug sensitivity tests in terms of the interval of reporting the result from the laboratory, as well as interval to the confirmation of results by physicians. In particular, the Xpert MTB/RIF assay shortened the time to initiation of anti-TB drugs by 14 days [24]. However, in this study, 53.8% of TB genexpert tests were out of the established TAT. This needs close follow up and monitoring to improve the Xpert MTB/RIF assay diagnostic service more.

As a limitation, this study was carried out using data from secondary sources that might underestimate the true delays of laboratory turnaround times and may also missed required information.

**Conclusions**

There was a delayed turnaround time of laboratory results in APHI. HIV viral load, EID and TB genexpert results were the most affected tests that need improvement. Workload reduction plan, proper stock management, specific work assignment and trained staff retention are important approaches to minimize the delayed TAT in the setting. Moreover, we recommend strong prospective studies to improve the laboratory services more.

**Abbreviations**

APHI: Amhara Public Health Institute; ART: Antiretroviral Therapy; EID: Exposed Infant Diagnosis; ISO: International Organization for Standardization; LIS: Laboratory Information System; TAT: Turnaround Time; TB: Tuberculosis

**Acknowledgements**

We would like to acknowledge the Amhara Public Health Institute for permission of the data to use for this research purpose. The study will not be possible without the cooperation of the institute.

**Funding**

The authors do not receive specific support or funding to report.

**Availability of data and materials**

All data supporting these findings is contained within the manuscript.
Authors' contributions
MBS designed the study. MBS and GY collected the data, analyzed and interpreted the findings. MBS drafted the manuscript. Both authors read and approved the submission of this manuscript.

Ethics approval and consent to participate
This study was reviewed and approved by the Amhara Public Health Institute. As it was a review of secondary data, support letter was found from the APHI research and technology transfer directorate to use the data for this research. We also requested permission from the central reception before extracting the data from the sample tracking log and from the LIS.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 November 2018 Accepted: 8 April 2019
Published online: 24 April 2019

References
1. International Organization for Standardization. ISO 15189:2012: medical laboratories—requirements for quality and competence. Geneva: ISO; 2012. Available at: http://www.iso.org/iso/catalogue_detail?csnumber=56115. Accessed 11 Nov 2018
2. Goswami B, Singh B, Chawla R, et al. Turnaround time (TAT) as a benchmark for laboratory and clinician. Indian J Hematol Blood Transfus. 2014;30:81–90.
3. Simonsen AH, Bahl JMC, Danborg PB, et al. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods. 2013;215:234–40.
4. Clinical and Laboratory Standard Institute (CLSI). Quality Management System: A model for Laboratory Services: Approved Guideline – Fourth Edition. Wayne: CLSI document QMS01-A4; 2011.
5. Erasmus RT, Zemlin AE. Clinical audit in the laboratory. J Clin Pathol. 2009;62:593–7.
6. Howanitz JH, Howanitz PJ. Laboratory results: Timeliness as a quality attribute and strategy. Am J Clin Pathol. 2001;116:311–5.
7. Hawkins RC. Laboratory turnaround time. Clin Biochem Rev. 2007;28:179–87.
8. Holland LL, Smith LL, Blick KE. Reducing laboratory turnaround time outliers can reduce emergency department patient length of stay. Am J Clin Pathol. 2005;124:672–3.
9. Ialongo C, Porzio O, Giambini I, Bernardini S. Total automation for the Core Laboratories: improving the turnaround time helps to reduce the volume of ordered STAT tests. J Lab Autom. 2016;21(3):451–8.
10. Imoh LC, Mutale M, Parker CT, et al. Laboratory-based clinical audit as a tool for continual improvement: an example from CSF chemistry turnaround time audit in a south-African teaching hospital. Biochem Med. 2016;26:194–201.
11. Pati HP, Singh G. Turnaround time (TAT): difference in concept for laboratory and clinician. Indian J Hematol Blood Transfus. 2014;30:81–4.
12. Ialongo C, Bernardini S. Validation of the six sigma Z-score for the quality assessment of clinical laboratory timeliness. Clin Chem Lab Med. 2018;56(4):595–601.
13. Coetzee LM, Cassim N, Glenross DK. Using laboratory data to categorise CD4 laboratory turn-around-time performance across a national programme. Afr J Lab Med. 2018;7(1):665.
14. Bilwani F, Siddiqui I, Vaqar S. Determination of delay in turnaround time (TAT) of stat tests and its causes: an AKUH experience. JMA. 2003;53:635–7.
15. Shamim A, Archana J, Sabila M, et al. Hidden trends of delay in turnaround time (TAT) in central pathology laboratory. PJMS. 2014;455–8.
16. Steindel SI, Jones BA, Howanitz PJ. Timeliness of automated routine laboratory tests: a College of American PathologistsQ - probes study of 653 institutions. Clin Chem Acta. 1996;251:25–40.
17. Minchella PA, Chipungu G, Kim AA, et al. Specimen origin, type and testing laboratory are linked to longer turnaround times for HIV viral load testing in Malawi. PLoS One. 2017;12(2):e0173009.
18. Ramadhani HO, Bartlett JA, Thielen NM, et al. The effect of switching to second-line antiretroviral therapy on the risk of opportunistic infections among patients infected with human immunodeficiency virus in northern Tanzania. Open Forum Infect Dis. 2016;3:ofw018. https://doi.org/10.1093/ofid/ofw018.
19. Mugavero MJ, Napravnik S, Cole SR, et al. Viremia copy-years predicts mortality among treatment-naïve HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis. 2011;53:927–35.
20. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS. 2011;25:843–50.
21. Petersen ML, Tran L, Gieng EH, et al. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014;28:2097–107.
22. Wecker C, Cheng AL, Gautney B, et al. Evaluating turnaround times for early infant diagnosis samples in Kenya from 2011-2014: a retrospective analysis of HIT system program data. PLoS One. 2017;12(8):e0181005.
23. Franke JA, Penazzato M, Hou T, et al. Clinical impact and cost-effectiveness of diagnosing HIV infection during early infancy in South Africa: test timing and frequency. J Infect Dis. 2016;214:1319–28.
24. Kwak N, Choi SM, Lee J, et al. Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practice. PLoS One. 2013;8(10):e77456.